Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A global study examining the impact of chloroquine / hydroxychloroquine in preventing COVID-19, COPCOV has recruited 3,386 participants as of 26 Oct from sites in Benin, Côte d’Ivoire, Indonesia, Kenya, Mali, Nepal, Pakistan, Zambia, and closed sites in Thailand, Niger and the UK. Last week, the COPCOV team agreed with active site research teams that it will continue to recruit new participants until 30 Nov 2021, with preliminary study results expected Q1 2022.

"After a slow start COPCOV has become the world’s largest study of COVID-19 chemoprophylaxis. Recent recruitment has been extraordinary. It is a great tribute to the participants and all those who have worked so hard on this important study. Let’s hope it provides a definitive answer early next year!" said COPCOV Co-PI, Prof Sir Nick White.

- With thanks to Nick White, Will Schilling and John Bleho for text.

Similar stories

Children with acute malnutrition and malaria: the double burden that increases risk of treatment failure

An analysis of over 11,000 falciparum malaria individual patient data sets has found that acutely malnourished children have a higher risk of reinfections and treatment failures, even when treated with recommended doses of artemisinin-based combination therapies, currently the best malaria treatment available. The malaria parasite clearance was also likely to be longer in these children.